Intestinal Antibody Responses to 2 Novel Live Attenuated Type 2 Oral Poliovirus Vaccines in Healthy Adults in Belgium.
Brickley, EB
; Connor, RI; Wieland-Alter, W; Weiner, JA; Ackerman, ME; Arita, M; Gast, C; De Coster, I; Van Damme, P; Bandyopadhyay, AS; +1 more...Wright, PF and
(2020)
Intestinal Antibody Responses to 2 Novel Live Attenuated Type 2 Oral Poliovirus Vaccines in Healthy Adults in Belgium.
The Journal of infectious diseases, 226 (2).
pp. 287-291.
ISSN 0022-1899
DOI: 10.1093/infdis/jiaa783
; Connor, RI; Wieland-Alter, W; Weiner, JA; Ackerman, ME; Arita, M; Gast, C; De Coster, I; Van Damme, P; Bandyopadhyay, AS; +1 more...Wright, PF and
(2020)
Intestinal Antibody Responses to 2 Novel Live Attenuated Type 2 Oral Poliovirus Vaccines in Healthy Adults in Belgium.
The Journal of infectious diseases, 226 (2).
pp. 287-291.
ISSN 0022-1899
DOI: 10.1093/infdis/jiaa783
In a blinded phase 1 trial (EudraCT 2017-0000908-21; NCT03430349) in Belgium, healthy adults (aged 18-50 years) previously immunized exclusively with inactivated poliovirus vaccine were administered a single dose of 1 of 2 novel type 2 oral poliovirus vaccines (nOPV2-c1: S2/cre5/S15domV/rec1/hifi3 (n = 15); nOPV2-c2: S2/S15domV/CpG40 (n = 15)) and isolated for 28 days in a purpose-built containment facility. Using stool samples collected near days 0, 14, 21, and 28, we evaluated intestinal neutralization and immunoglobulin A responses to the nOPV2s and found that nOPV2-c1 and nOPV2-c2 induced detectable poliovirus type 2-specific intestinal neutralizing responses in 40.0% and 46.7% of participants, respectively.
-
picture_as_pdf - jiaa783.pdf
-
subject - Accepted Version
-
error - This is an author accepted manuscript version of an article accepted for publication, and following peer review. Please be aware that minor differences may exist between this version and the final version if you wish to cite from it
-
- Available under Creative Commons: Attribution-NonCommercial-No Derivative Works 3.0
Downloads